

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

G Medical Innovations Holdings Ltd

ABN

617 204 743

Quarter ended ("current quarter")

30 June 2018

Consolidated statement of cash flows	Current quarter \$US'000	Year to date (6 months) \$US'000*
1. Cash flows from operating activities		
1.1 Receipts from customers	356	617**
1.2 Payments for		
(a) research and development	(483)	(725)
(b) product manufacturing and operating costs	(270)	(860)
(c) advertising and marketing	(474)	(883)
(d) leased assets	-	-
(e) staff costs	(2,853)	(5,078)
(f) administration and corporate costs	(896)	(1,914)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(245)	(165)
1.6 Income taxes paid	(14)	(29)
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	(100)	(68)
1.9 Net cash from / (used in) operating activities	(4,979)	(9,105)

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	(443)	(2,073)
(b) businesses (see item 10)	-	-
(c) investments	-	-

Consolidated statement of cash flows		Current quarter \$US'000	Year to date (6 months) \$US'000*
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	-	91
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (restricted deposits)	(201)	(660)
2.6	Net cash from / (used in) investing activities	(644)	(2,642)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of shares	-	-
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares, convertible notes or options	-	-
3.5	Proceeds from borrowings	1,500	1,559
3.6	Repayment of borrowings	(391)	(799)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	1,109	760

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	7,685	14,158
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(4,979)	(9,105)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(644)	(2,642)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,109	760

Consolidated statement of cash flows		Current quarter \$US'000	Year to date (6 months) \$US'000*
4.5	Effect of movement in exchange rates on cash held	33	33
4.6	Cash and cash equivalents at end of quarter/ year to date	3,204	3,204

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$US'000	Previous quarter \$US'000*
5.1	Bank balances	3,204	7,685
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	3,204	7,685

*The Company advised that the previous March quarter Appendix 4C had the currency denomination in the column heading stated as \$A'000, however the numbers included in the column were in \$US'000. The heading has now been corrected to state \$US'000.

**The Company advises that cash flows from G Medical Diagnostic Services (GMedDX) in the US are expected to commence materially in Q3 2018.

6.	Payments to directors of the entity and their associates	Current quarter \$US'000
6.1	Aggregate amount of payments to these parties included in item 1.2	155
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	

The amount represents in 6.1 relates to the remuneration payable to the Directors and to the President and CEO.

7. Payments to related entities of the entity and their associates	Current quarter \$US'000
7.1 Aggregate amount of payments to these parties included in item 1.2	-
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$US'000	Amount drawn at quarter end \$US'000
8.1 Loan facilities	3,505	3,505
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	3,511	2,011
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

8.1- The Company received several loans from Bank Mizrahi Tfahot in Israel. As of June 30, 2018, the total amount of these loans is: US\$ 2.008 M.

The loans are denominated in US Dollars and NIS and bear interest rates of Libor + (2.5%-3%) and prime+ (0.5%- 0.85%) per annum.

The Company's major shareholder provides a guarantee for part of these loans payments.

Upon CardioStaff acquisition, additional long- term loans were added to the Company balance.

As of June 30, 2018, the total amount of these loans is US\$ 1.497 M and include mainly loans from private people/institutions and bear interest of 4%-12% per annum.

8.3- Loans from controlling shareholder (Yacov Geva)- In addition to the previous loan with the Company of US\$0.5 M (bear interest of Libor +3%), Yacov Geva has entered into a loan agreement in May 2018, to provide the Company with a loan of up to US\$ 3M.

As of June 30, 2018, the total amount of this loan that is available is US\$1.5 M.

9. Estimated cash outflows for next quarter	\$US'000
9.1 Research and development	400
9.2 Product manufacturing and operating costs	750
9.3 Advertising and marketing	200
9.4 Leased assets	
9.5 Staff costs	2,050
9.6 Administration and corporate costs	800
9.7 Other (provide details if material)	750
9.8 Total estimated cash outflows	4,950

Notes:

9.7 includes expenditure for the purchase of fixed assets for approximately US\$150k and the repayment of borrowings for approximately US\$500k.

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity	-	-
10.2 Place of incorporation or registration	-	-
10.3 Consideration for acquisition or disposal	-	-
10.4 Total net assets	-	-
10.5 Nature of business	-	-

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

[lodged electronically without signature]

31 July 2018

Sign here:
(Director/Company secretary)

Date:

Steven Wood

Print name:

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.